AI주식인사이트AI Stock Insight
D

서울제약

018680KOSDAQ의약품 제조업

37.5 / 100

Reference Date: 2026-06-10

Financial Score9.0 / 40
News Sentiment12.5 / 25
Momentum6.0 / 20
Disclosure10.0 / 15
AI Analysis: PBR is significantly undervalued vs. peers but the high debt ratio poses financial risk. Plunged 19.4% over the past month, with no recent news.

Company InformationBased on 2025 Annual Report

Business Overview

Seoul Pharmaceutical focuses on developing improved new drugs and innovative drug delivery technologies, such as SmartFilm® Technology, to maintain competitiveness in the global pharmaceutical market. Key products like Ator, a cholesterol-lowering medication, drive growth, with sales reaching 53,580 million KRW and operating profit increasing by 26% in 2024. The company is expanding its market share in chronic disease areas and preparing to launch first-generic products ahead of patent expirations.

Number of Employees

132people

Average Salary

65.8M KRW

Score Calculation Basis

Detailed Financial Score

PER
33.85Industry Average 11.930.0Point

2.8x industry avg (risky)

PBR
0.62Industry Average 0.895.5Point

Lower than industry avg (good)

ROE
1.86Industry Average 4.011.0Point

Well below industry avg

Debt Ratio
38.51Industry Average 12.430.0Point

3.1x industry avg (risky)

Trend 2023~20252.5 / 10 points
Revenue Growth Rate
0.5 / 3

Avg ▼0.3% (2-year basis)

Operating Profit Growth Rate
0.0 / 3

Avg ▼78.9% (2-year basis)

ROE Trend
2.0 / 4

Avg ROE 5.2% (declining, 3yr)

Detailed News Sentiment

0 totalPositive 0Neutral 0Negative 0

Detailed Momentum

52-week position1.0Point

Near 52w low (0%, downtrend)

Current 2,200Won52-week high 3,56552-week low 2,190
1-month return0.0Point

1m -19.41% (strong drop)

Volume trend5.0Point

Volume flat

Detailed Disclosure

2 totalPositive 0Neutral 2Negative 0
  • Neutral대규모기업집단현황공시[연1회공시및1/4분기용(개별회사)]2026-06-01
  • Neutral분기보고서 (2026.03)2026-05-15